A carregar...
Both cladribine and alemtuzumab may effect MS via B-cell depletion
OBJECTIVE: To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies. METHODS: The regulatory submissions of the CLAD Tablets Treating Multiple...
Na minha lista:
| Publicado no: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5459792/ https://ncbi.nlm.nih.gov/pubmed/28626781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000360 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|